An observational study in Breast Cancer Surgery, sponsored by Sir Mortimer B. Davis - Jewish General Hospital. Recruiting at 16 sites in 8 countries. Open to female participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by Sir Mortimer B. Davis - Jewish General Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Li-Fraumeni Syndrome with a site in United States — 8 open to participants now, 9 under way, none of them phase 3. Li-Fraumeni Syndrome · United States.
Among the 14 studies in Li-Fraumeni Syndrome with a site in United States, this one is the 3rd largest by planned enrollment of the 12 observational ones that give a count, is one of 2 that started in 2025, is one of 12 observational ones, and was the 12th registered.
25 studies on the registry are indexed under Li-Fraumeni Syndrome; 16 are open to participants now.
Browse Li-Fraumeni Syndrome studies →8 of the 14 studies in Li-Fraumeni Syndrome with a site in United States are open now. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Dana-Farber Cancer Institute · Sites in United States
Abramson Cancer Center at Penn Medicine · Sites in United States
Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
National Cancer Institute (NCI) · Sites in United States
Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Li-Fraumeni Syndrome studies recruiting now, 9 (69%) set no upper age limit and 1 (8%) stops at 75 or younger; 9 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 90 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 4,700 is above the median of 439 across 18 observational studies indexed under Li-Fraumeni Syndrome.
Median enrollment 88 across the 2 interventional studies, 750 across the 12 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 14 has an industry lead sponsor. The 8 most frequent:
Sir Mortimer B. Davis - Jewish General Hospital is the lead sponsor of 62 studies on the registry; 22 are open to participants now.
Sir Mortimer B. Davis - Jewish General Hospital has 1 study filed under Li-Fraumeni Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Li-Fraumeni Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06888388Sir Mortimer B. Davis - Jewish General HospitalLong-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer | 2027-02-01 |
| NCT05126810M.D. Anderson Cancer CenterWillingness to Participate in a Trial Comparing Standard Genetic Counseling Versus Personalized Genetic Counseling | 2027-02-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Li-Fraumeni Syndrome with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Patients with a germline pathogenic variant (GPV) in high-penetrance breast cancer susceptibility genes who are considering risk reducing mastectomy (RRM) often strongly desire to keep their nipple areola complex but inquire as to whether it is safe to do so. Relative to traditional or skin sparing mastectomy (SSM) techniques, nipple sparing mastectomy (NSM) is associated with improved psychosocial and sexual well-being and is significantly better for body image and reducing feelings of disfigurement.
Despite this, guidelines have yet to endorse the use of NSM over other RRM techniques, stating that more data and longer follow-up are needed to confirm it as a safe and effective strategy in GPV carriers. As NSM was not routinely adopted in high-risk patient populations undergoing RRM before 2010, there has been little data to inform the long-term oncologic safety of NSM. Well-designed studies have reported low to negligible rates of subsequent breast cancer in BRCA1/2 carriers following NSM, but have been limited by short median follow-up of less than 3 years. The current study is designed to confirm, with longer follow-up, prior findings on the oncologic safety of NSM in unaffected BRCA1/2 carriers. The investigators will also expand data to other high-penetrance GPV carriers, including PALB2, CDH1, PTEN, and TP53, for whom there is little-to-no data on outcomes following RRM.
Female patients aged 18-years or older with a confirmed GPV in BRCA1, BRCA2, PALB2, TP53, CDH1 or PTEN identified on pre-symptomatic genetic testing performed between January 1, 1994-June 30, 2024
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Procedure: Nipple Sparing Mastectomy (NSM) · Procedure: Skin-Sparing Mastectomy (SSM) · Procedure: Total (Simple) Mastectomy
Nipple sparing mastectomy (NSM) is a surgical procedure which removes all macroscopic breast glandular tissue while retaining the skin as well as the nipple areola complex.
Skin sparing mastectomy (SSM) is a procedure that removes the nipple and areola complex along with all visible macroscopic breast glandular tissue.
Total (Simple) Mastectomy is a traditional mastectomy approach that removes the breast glandular tissue with a large overlying area of skin including the nipple and areola complex to allow for flat closure.
Incidence of breast cancer following RRM
The primary outcome of interest is the incidence of breast cancer following RRM, defined as a histologically confirmed diagnosis of in situ or invasive breast cancer present within the nipple/areola, skin, subcutaneous tissue of the chest wall/reconstructed breast, or axillary lymph nodes. Patients with clinically occult invasive breast cancer diagnosed at the time of RRM (ie. on mastectomy pathology) will be excluded from the primary outcome analysis.
Time frame: 10 years
Incidence of RRM
To evaluate uptake of RRM versus active surveillance amongst an international cohort of unaffected women with high-penetrance GPVs in BRCA1/2, PALB2, CDH1, PTEN, or TP53
Time frame: 10 years
Incidence of post-operative complications
To evaluate post-operative complications and supplemental surgery following NSM, SSM, and total mastectomy in those undergoing RRM
Time frame: 10 years
Incidence of pathologic outcomes following NSM
To evaluate pathologic outcomes following RRM, including the presence of high-risk lesions or occult in situ and/or invasive malignancy
Time frame: 10 years
Number of participants using endocrine prevention
To explore the use of endocrine prevention in unaffected women with high-penetrance GPVs in BRCA1/2, PALB2, CDH1, PTEN, or TP53 who elect to undergo active surveillance
Time frame: 10 years
Number of participants who have undergone pre-mastectomy imaging and post-mastectomy surveillance
To assess practices in pre-mastectomy imaging and post-mastectomy surveillance, including the number of participants who underwent preoperative MRI and mammography as well as post-mastectomy surveillance, including MRI, ultrasound and chest wall examination.
Time frame: 10 years
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Feb 2027, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sir Mortimer B. Davis - Jewish General Hospital